Cosmo Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Cosmo Pharmaceuticals has a total shareholder equity of €505.4M and total debt of €559.0K, which brings its debt-to-equity ratio to 0.1%. Its total assets and total liabilities are €638.3M and €132.9M respectively. Cosmo Pharmaceuticals's EBIT is €86.0M making its interest coverage ratio 154.4. It has cash and short-term investments of €133.4M.
Key information
0.1%
Debt to equity ratio
€559.00k
Debt
| Interest coverage ratio | 154.4x |
| Cash | €133.41m |
| Equity | €505.39m |
| Total liabilities | €132.87m |
| Total assets | €638.25m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0RGI's short term assets (€183.6M) exceed its short term liabilities (€37.9M).
Long Term Liabilities: 0RGI's short term assets (€183.6M) exceed its long term liabilities (€95.0M).
Debt to Equity History and Analysis
Debt Level: 0RGI has more cash than its total debt.
Reducing Debt: 0RGI's debt to equity ratio has reduced from 38.9% to 0.1% over the past 5 years.
Debt Coverage: 0RGI's debt is well covered by operating cash flow (20988.6%).
Interest Coverage: 0RGI's interest payments on its debt are well covered by EBIT (154.4x coverage).